DOCSLIB.ORG

Caffeine Or Theophylline for Neonatal Apnoea?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Caffeine Or Theophylline for Neonatal Apnoea? Archives ofDisease in Childhood 1992; 67: 425-428 425 Arch Dis Child: first published as 10.1136/adc.67.4_Spec_No.425 on 1 April 1992. Downloaded from Caffeine or theophylline for neonatal apnoea? J E M Scanlon, K C Chin, M E I Morgan, G M Durbin, K A Hale, S S Brown Abstract a higher dose of caffeine than that previously Caffeine, in the dose usualiy recommended recommended was required to treat effectively (12-5 mg/kg loading dose and 3 mg/kg daily infants of lower gestational age. This study was maintenance), and a higher dose regimen (25 therefore designed to compare the efficacy of mg/kg loading and 6 mg/kg daily maintenance), theophylline with that of caffeine administered was compared with theophylline (7.5 mg/kg in two different dose regimens to a group of loading and 3 mg/kg thrice daily maintenance). very preterm infants with frequent and clinically The study was a randomised controiled trial significant apnoeic attacks. in the treatment of a group of44 infants of less than 31 weeks' gestation (mean gestational age 28.3 weeks) who were suffering from Patients and methods frequent apnoeic attacks. AU three regimens PATIENT SELECTION produced a significant reduction in apnoeic Infants were included in our study if they were attacks within 24 hours, but only the higher less than 31 weeks' gestation at birth and if they dose caffeine and theophyfline groups showed had either 10 (or more) apnoeic attacks in eight a significant improvement in apnoea within hours or four apnoeas in one hour. Apnoea was eight hours. defined as a drop in heart rate of more than 40 The use of caffeine for the treatment of beats/minute (bpm) below the resting heart rate neonatal apnoea is recommended, because a in an infant who was not breathing, and who once daily dose is more easily administered, required stimulation to correct the problem. and because it was found that plasma concen- Infants prospectively entering the trial were trations were more predictable than those of randomly allocated (by random numbers in theophylline. If used in very preterm infants, sealed envelopes) to one of three treatment however, its is suggested that a higher dose groups. Group A ('standard dose caffeine')-a regimen than that previously recommended loading dose of 25 mg/kg caffeine citrate (12-5 be used to achieve a faster response. mg/kg caffeine) and a maintenance dose of 6 mg/kg caffeine citrate (3 mg/kg caffeine) once daily were given to produce a desired plasma http://adc.bmj.com/ Neonatal apnoea is a common problem: it concentration of 15 mg/l caffeine (range 13-20 occurs in 25% of infants under 2500 g and 80% mg/l). Group B ('higher dose caffeine')-a of infants under 1000 g.1 2 With smaller babies loading dose of 50 mg/kg caffeine citrate now forming a large percentage ofthe population (25 mg/kg caffeine) and maintenance dose of of neonatal intensive care units, the manage- 12 mg/kg (6 mg/kg caffeine) once daily were ment of neonatal apnoea is an important part of given to produce a desired plasma concentration the clinical workload. of 30 mg/l (range 26-40 mg/l). Group C ('theo- on September 26, 2021 by guest. Protected copyright. The methylxanthines-theophylline (and phylline')-a loading dose of 7.5 mg/kg theo- aminophylline) and caffeine-are widely used phylline and a maintenance dose of 3 mg/kg for the treatment of this condition.3 Theophyl- theophylline three times daily were given to to concentration of Regional Neonatal line has been the drug most commonly used produce a desired plasma Intensive Care Unit, treat neonatal apnoea in the UK.4 5 Caffeine, 15 mg/l (range 13-20 mg/l). Birmingham Maternity however, has many potential advantages: it has In all three treatment groups the maintenance Hospital, Institute of a therapeutic ratio, it is absorbed more dose of the drug was adjusted if the plasma Child Health, higher Birmingham reliably when administered enterally and has a concentrations were out of the desired range, J E M Scanlon longer half life, thus enabling the drug to be but in none of these patients were such adjust- K C Chin administered only once daily.6 Caffeine has also ments made within 48 hours of starting treat- M E I Morgan G M Durbin been shown to be effective in apnoeic infants ment. As theophylline is metabolised into the cumu- Regional Laboratory who are unresponsive to theophylline.7 caffeine in the premature infant," for Toxicology, Comparisons of the two drugs have been lated caffeine plus theophylline concentrations Dudley Road Hospital, reported before,"'0 but these studies have in this group were kept below 25 mg/l. Birmingham K A Hale either included a high proportion of more S S Brown mature infants (of 31 or 32 weeks' gestation), or DRUGS Correspondence to: excluded oxygen dependent infants included Dr J E M Scanlon, infants with as few as three apnoeas per day. The drugs were usually given orally or via a Department of Paediatrics, Southampton General They therefore failed to reflect the day to day nasogastric tube. The preparations used for oral Hospital, Tremona Road, problems in most neonatal intensive care units administration were caffeine citrate in chloro- Southampton S09 4XY. in their management of very preterm infants form water (20 mg caffeine citrate/ml) and Accepted 13 December 1991 with apnoeic attacks. theophylline hydrate in 90% alcohol diluted No reprints available. In a pilot study we formed an impression that with water (3 mg theophylline/ml). Although 426 Scanlon, Chin, Morgan, Durbin, Hale, Brown these are the preparations that we are still using, chromatography on 100 tl of plasma (minimum Arch Dis Child: first published as 10.1136/adc.67.4_Spec_No.425 on 1 April 1992. Downloaded from recent work has shown that the preservatives in 50 ,ul plasma). these mixtures (that is, chloroform water and 90% alcohol) are not essential, and that caffeine and theophylline are pharmacologically stable STATISTICS and microbiologically safe for a period of one Statistical analysis of results was performed week having been made up in purified water using Fisher's exact test and Student's paired and stored in a refrigerator (Tina Crook, Royal t test as appropriate. Berkshire Hospital, pharmacy department- This project was approved by the ethical personal communication). committee of Central Birmingham Health When using the 'higher dose caffeine' regi- Authority. men the loading dose was administered in two separate doses of 25 mg/kg caffeine citrate given orally one hour apart, in order to avoid the Results possibility of the infant vomiting because of the Over a two year period 44 infants were entered volume load. into the study. Of the 44 infants, 32 (73%) had Caffeine citrate 0-99% (caffeine citrate 10 previously been ventilated and 43 (98%) were mg/ml)-both loading dose and maintenance still oxygen dependent at the time of entry to doses infused daily over half an hour-and the study. Twenty six infants (59%) were boys aminophylline injection (aminophylline 25 and 37 (84%) were white. mg/ml)-administered as a continuous in- Although every attempt was made to exclude fusion-were available as alternatives to oral or other causes of apnoea, eight infants were nasogastric treatment in our trial. None of the subsequently found to have other problems and infants in group B (higher dose caffeine) or it became clear that their apnoeic attacks were group C (theophylline) received intravenous secondary to these other diagnoses: four infants treatment. Only two infants in group A (stan- had proven infection (pneumonia and septi- dard dose caffeine)receivedintravenous caffeine, caemia with positive blood cultures), two and neither their clinical response nor the infants had significant neurological abnormality plasma concentrations of caffeine different (bilateral periventricular leucomalacia with appreciably from the other infants in that subsequent abnormal neurological development) group. We have treated large numbers of other and two had severe oesophageal reflux (as infants with both caffeine citrate and amino- demonstrated by an intraoesophageal pH phylline administered intravenously, and have probe. 12 observed no differences, clinically or with Table 1 shows the characteristics of the plasma concentrations, related to route of infants in the trial. There were no significant administration. differences between the groups in weight, gesta- tional age, or postnatal age and the sex distribu- tion of the infants within the groups showed an MEASUREMENTS OF PLASMA CONCENTRATIONS OF approximately equal male to female ratio. THE DRUGS http://adc.bmj.com/ Blood samples for measurement of drug concen- trations were obtained at the same time as blood RESPONSE TO TREATMENT sampling for other routine tests: all were The number of apnoeas (over a 24 hour period) heparinised capillary samples taken from the decreased dramatically over two days from the heel. They were obtained daily for five days, start of treatment in all three groups, but was starting the day after the loading dose, and most significant in the high dose caffeine and twice during the course of the next week. theophylline groups. on September 26, 2021 by guest. Protected copyright. Plasma theophylline and caffeine concentrations As can be seen in table 2, which includes the were determined by high performance liquid results from all infants entered, the number of apnoeas/day was reduced by a third within 24 hours by treatment with standard dose Table I Characteristics of infants entering the trial (n=44). Weight and age figures are caffeine. It was, however, reduced by over 50% mean (SD) by the higher dose caffeine and theophylline No of Birth weight Gestational Postnatal M:F treatments within the same time period.
Load more

Recommended publications
  • Additions and Deletions to the Drug Product List
    Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 09 : September 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA STRIDES PHARMA 325MG;50MG;40MG A 203647 001 Sep 21, 2020 Sep NEWA ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >D> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC >A> @ 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA NOSTRUM LABS INC 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >A> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >A> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN >D> AA TEVA 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >D> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >D> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> @ CEROVENE INC 325MG;5MG A 211690 001 Feb 07, 2020 Sep CAHN >A> @ 325MG;7.5MG A 211690 002 Feb 07, 2020 Sep CAHN >A> @ 325MG;10MG A 211690 003 Feb 07, 2020 Sep CAHN >D> AA VINTAGE PHARMS 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >A> @ 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >D> AA 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >A> @ 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >D> AA 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >A> @ 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >D> @ XIROMED 325MG;5MG A 211690
    [Show full text]
  • Neonatal Intensive Care Drug Therapy Update: a Bibliography
    LWW/JPNN AS310-13 July 28, 2004 23:11 Char Count= 0 J Perinat Neonat Nurs Vol. 18, No. 3, pp. 292–306 c 2004 Lippincott Williams & Wilkins, Inc. Neonatal Intensive Care Drug Therapy Update: A Bibliography Jason Sauberan, PharmD BIBLIOGRAPHY I. Overview A. Clark RH, Bloom BT, Gerstmann DR Medications Used in Neonatal Intensive Care Units—A Descriptive Study [abstract 3047]. In: Program and abstracts of the 2004 Pediatric Academic Societies’ Annual Meeting, San Francisco, CA. B. Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R, Berkovitch M. Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study. Am J Perinatol. 2002 Feb;19(2):67–72. C. O’Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics. 2002 Nov;110(5):e52. D. Committee on Drugs. American Academy of Pediatrics. Uses of drugs not described in the package insert (off-label uses). Pediatrics. 2002 Jul;110(1 Pt 1):181–3. II. Anti-infectives A. Linezolid 1. Deville JG, Adler S, Azimi PH, Jantausch BA, Morfin MR, Beltran S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J. 2003 Sep;22(9 Suppl):S158–63. 2. Vo M, Cirincione BB, Rubino CM, Jungbluth GL. Pharmacokinetics of Linezolid in Neonates and Young Infants [abstract A-1409]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA.
    [Show full text]
  • Effect of Aminophylline on Diaphragmatic Contractility in the Piglet
    003 1-3998/90/2803-0196$02.00/0 PEDIATRIC RESEARCH Vol. 28, No. 3, 1990 Copyright 0 1990 International Pediatric Research Foundation, Inc. Printed in (I.S.A. Effect of Aminophylline on Diaphragmatic Contractility in the Piglet DENNIS E. MAYOCK, THOMAS A. STANDAERT, JON F. WATCHKO, AND DAVID E. WOODRUM1 University of Washington School of Medicine, Department of Pediatrics, Division of Neonatal and Respiratory Diseases, Seattle, Washington 98195 ABSTRACT. Minute ventilation, arterial blood gases, ar- of arterial oxygen > 8 kPa (60 torr) in room air, and a partial terial pH, cardiac output, and transdiaphragmatic force pressure of the arterial carbon dioxide 5 6.7 kPa (50 torr) were generation, both during spontaneous ventilation and in accepted for study. The animals were anesthetized with an i.v. response to phrenic nerve stiwulation during airway occlu- combination of chloralose (30 mg/kg) and urethane (1 50 mg/ sion at end expiration, were measured in nine anesthetized, kg) and studied in the supine position. Subsequent infusions of tracheostomized piglets before and 30 min after parenteral anesthetic were used if the piglet developed jaw clonus. A trache- infusion of 20 mg/kg aminophylline. Serum theophylline ostomy was placed and connected to a two-way nonrebreathing levels averaged 109 f 21 ~mol/L(19.7 f 3.7 ~g/mL)at valve (model 2384, Hans Rudolph, Inc., Kansas City, MO). 30 min postinfusion. No significant changes were noted in Inspiratory flow was detected by a hot-wire anemometer and pH, blood gases, blood Pressure, or ventilatory measures integrated to provide tidal volume. All animals breathed 50% after aminophylline.
    [Show full text]
  • Aminophylline Catalog Number A1755 Storage
    Aminophylline Catalog Number A1755 Storage Temperature –20 °C Replacement for Catalog Number 216895 CAS RN 317-34-0 Storage/Stability Synonyms: theophylline hemiethylenediamine complex; Aminophylline should be kept tightly closed to prevent 3,7-dihydro-1,3-demethyl-1H-purine-2,6-dione CO2 absorption from the atmosphere, which leads to compound with 1,2-ethanediamine (2:1); formation of theophylline and decreased solubility in 1,2 3 (theophylline)2 • ethylenediamine aqueous solutions. Stock solutions should be protected from light and prevented from contact with Product Description metals.2 Molecular Formula: C7H8N4O2 ·1/2 (C2H8N2) Molecular Weight: 210.3 References 1. The Merck Index, 12th ed., Entry# 485. Aminophylline is a xanthine derivative which is a 2. Martindale: The Extra Pharmacopoeia, 31st ed., combination of theophylline and ethylenediamine that is Reynolds, J. E. F., ed., Royal Pharmaceutical more water soluble than theophylline alone. Society (London, England: 1996), pp. 1651-1652. Aminophylline has been widely used as an inhibitor of 3. Data for Biochemical Research, 3rd ed., Dawson, cAMP phosphodiesterase.3 R. M. C., et al., Oxford University Press (New York, NY: 1986), pp. 316-317. Aminophylline has been shown to limit 4. Pelech, S. L., et al., cAMP analogues inhibit phosphatidylcholine biosynthesis in cultured rat phosphatidylcholine biosynthesis in cultured rat hepatocytes.4 It has been used in studies of acute hepatocytes. J. Biol. Chem., 256(16), 8283-8286 hypoxemia in newborn and older guinea pigs.5 The (1981). effect of various xanthine derivatives, including 5. Crisanti, K. C., and Fewell, J. E., Aminophylline aminophylline, on activation of the cystic fibrosis alters the core temperature response to acute transmembrane conductance regulator (CFTR) chloride hypoxemia in newborn and older guinea pigs.
    [Show full text]
  • Rosemary)-Derived Ingredients As Used in Cosmetics
    Safety Assessment of Rosmarinus Officinalis (Rosemary)-Derived Ingredients as Used in Cosmetics Status: Tentative Amended Report for Public Comment Release Date: March 28, 2014 Panel Meeting Date: June 9-10, 2014 All interested persons are provided 60 days from the above release date to comment on this safety assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Director, Dr. Lillian J. Gill. The 2014 Cosmetic Ingredient Review Expert Panel members are: Chairman, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Director is Lillian J. Gill, D.P.A. This safety assessment was prepared by Monice M. Fiume, Assistant Director/Senior Scientific Analyst. © Cosmetic Ingredient Review 1620 L Street, NW, Suite 1200♢ Washington, DC 20036 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢ [email protected] TABLE OF CONTENTS Abstract ......................................................................................................................................................................................................................................
    [Show full text]
  • Application and Review of Pediatric Pharmacotherapy, Sample Chapter
    Application and Review of Pediatric Pharmacotherapy Chapter No. 1 Dated: 29/7/2010 At Time: 16:16:4 Section 1 Neonatal intensive care “Luck is where preparation meets opportunity.” This section consists of 16 medication orders followed by corresponding patient profiles representing pharmacotherapy associated with patients admit- ted to a neonatal intensive care unit. Each patient profile is followed by multiple-choice questions pertaining to the medication order and profile infor- mation. Choose the one best-lettered response to each item. The correct answers are provided at the end of this section. The reader is encouraged to attempt all questions for each case or for the entire section prior to referring to the answers. Moreover, where appropriate, the answer key provides a thor- ough explanation of the correct response and should serve as an additional learning tool for the reader. Application and Review of Pediatric Pharmacotherapy Chapter No. 1 Dated: 29/7/2010 At Time: 16:16:4 2 | Application and Review of Pediatric Pharmacotherapy Medication orders Physician order Patient weight: 2.5 kg Aminophylline 10 mg iv load, then begin 2.5 mg iv q 12 h Obtain theophylline concentration 1 h postinfusion of loading dose Date/time: 12/01/2100 Patient name: Baby Boy Turner Physician: John Craver Patient ID: 111222 Medical profile Patient: Baby Boy Turner Patient weight: 2.5 kg Age: 1d/o Present illness: Apneic episodes Allergies: None Medical history: 33 weeks gestation, Apgar 7 and 9 Labs: pending Medication profile Questions Q1 Which of the following is an acceptable definition of apnea of prematurity? 1 o cessation of breathing for less than 20 s 2 o cessation of breathing for at least 20 s 3 o cessation of breathing for less than 20 s when accompanied by bradycardia A o 1 only B o 3 only C o 1 and 3 only Application and Review of Pediatric Pharmacotherapy Chapter No.
    [Show full text]
  • Caffeine in the Treatment of Pain
    Rev Bras Anestesiol ARTIGOS DE REVISÃO 2012; 62: 3: 387-401 ARTIGOS DE REVISÃO Cafeína para o Tratamento de Dor Cristiane Tavares, TSA 1, Rioko Kimiko Sakata, TSA 2 Resumo: Tavares C, Sakata RK – Cafeína para o Tratamento de Dor. Justificativa e objetivos: A cafeína é uma substância amplamente consumida com efeitos em diversos sistemas e que apresenta farmacoci- nética e farmacodinâmica características, causando interações com diversos medicamentos. O objetivo deste estudo é fazer uma revisão sobre os efeitos da cafeína. Conteúdo: Nesta revisão, são abordados a farmacologia da cafeína, os mecanismos de ação, as indicações, as contraindicações, as doses, as interações e os efeitos adversos. Conclusões: Faltam estudos controlados, randomizados e duplos-cegos para avaliar a eficácia analgésica da cafeína nas diversas síndromes dolorosas. Em pacientes com dor crônica, é necessário ter cautela em relação ao desenvolvimento de tolerância, abstinência e interação medi- camentosa no uso crônico de cafeína. Unitermos: ANALGESIA; DOR; DROGAS, Alcaloide/cafeína. ©2012 Elsevier Editora Ltda. Todos os direitos reservados. INTRODUÇÃO Estrutura química A cafeína foi isolada em 1820, mas a estrutura correta des- A cafeína é um alcaloide presente em mais de 60 espécies ta metilxantina foi estabelecida na última década do século de plantas 4. Sua estrutura molecular pertence a um grupo XIX. Os efeitos não foram claramente reconhecidos até 1981, de xantinas trimetiladas que incluem seus compostos inti- quando o bloqueio de receptores adenosina foi correlacio- mamente relacionados: teobromina (presente no cacau) e nado às propriedades estimulantes da cafeína e de seus teofilina (presente no chá) 1. Quimicamente, esses alcaloides análogos 1. Provavelmente a cafeína é uma das substâncias são semelhantes a purinas, xantinas e ácido úrico, que são psicoativas mais utilizadas no mundo, promovendo efeitos compostos metabolicamente importantes 4.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Proxyphylline Item No. 20937 CAS Registry No.: 603-00-9 Formal Name: 3,7-dihydro-7-(2-hydroxypropyl)-1,3- N dimethyl-1H-purine-2,6-dione O N Synonym: NSC 163343 C H N O MF: 10 14 4 3 N FW: 238.2 N Purity: ≥98% O UV/Vis.: λmax: 273, 324 nm Supplied as: A crystalline solid OH Storage: -20°C Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly Laboratory Procedures Proxyphylline is supplied as a crystalline solid. A stock solution may be made by dissolving the proxyphylline in the solvent of choice. Proxyphylline is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of proxyphylline in ethanol is approximately 1 mg/ml and approximately 10 mg/ml in DMSO and DMF. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of proxyphylline can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of proxyphylline in PBS, pH 7.2, is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description Proxyphylline is a methylxanthine derivative that has bronchodilatory actions.1 It has also been reported 2 to have vasodilatory and cardiac stimulatory effects.
    [Show full text]
  • Caffeine Citrate 10Mg/Ml Oral Solution Maintenance Doses
    PACKAGE LEAFLET: INFORMATION FOR THE PATIENT doctor or nurse may give one more higher • changes in blood tests (reduced levels dose, before continuing to the lower of haemoglobin after prolonged Caffeine Citrate 10mg/ml Oral Solution maintenance doses. treatment) Duration of treatment • reduced thyroid hormone at the start Equivalent to Caffeine 5mg/ml Your baby’s doctor will decide exactly of treatment with other medicines given at the same Please read all of this leaflet carefully how long your newborn must continue Reporting of side effects time. A premature baby may need many before your baby is given this therapy with Caffeine Citrate 10mg/ml If your newborn gets any side effects, medicines, and any problems with caffeine medicine. Oral Solution. If your baby has 5 to 7 days talk to your baby’s doctor. This includes are likely to be minor, but tell the doctor • Keep this leaflet. You may need to read without apnoea attacks, the doctor will any possible side effects not listed in this about any other medication they may it again. stop treatment. leaflet. You can also report side effects D04359 not know about, particularly any other • If you have further questions, please The doctor may decide to check the directly via Yellow Card Scheme. medicine (for example theophylline) given ask the hospital doctor who is looking levels of caffeine in a blood sample Website: www.mhra.gov.uk/yellowcard to your baby to help it breathe. after your baby. as a precaution, or if your baby is not or search for MHRA Yellow Card in the If your newborn gets any side effects, Medications containing phenobarbitone responding to treatment as expected.
    [Show full text]
  • Caffeine Versus Aminophylline for Apnea of Prematurity: a Randomized Clinical Trial
    World Journal of Peri & Neonatology Vol. 2, No. 2, Fall 2019 Original Article http://wjpn.ssu.ac.ir Caffeine versus Aminophylline for Apnea of Prematurity: A Randomized Clinical Trial Mohamad Hosein Lookzadeh 1,2, Elaha Jafari-Abeshoori 2*, Mahmood Noorishadkam 1,2, Seyed Reza Mirjalili 1,2, Hamid Reza Mohammadi 3, Fatemeh Emambakhshsani 2 1 Department of Pediatrics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran 2 Mother and Newborn Health Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran 3 Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran Received: 04 April 2020 Revised: 16 June 2020 Accepted: 20 July 2020 ARTICLE INFO ABSTRACT Corresponding author: Background: Apnea of prematurity is often found in preterm neonates Elaha Jafari-Abeshoori with gestational age less than 34-37 weeks or birth weight (BW) less than 1000 grams. The American Academy of Pediatrics defines apnea as a Email: [email protected] respiratory halt lasting at least 20 seconds, with bradycardia or cyanosis. Methylxanthines reduce the incidence of apnea. The purpose of this study Keywords: was to compare the effect of caffeine and aminophylline on the incidence Aminophylline, of the apnea in premature infants. Caffeine, Methods: This randomized clinical trial study was conducted on 80 Apnea, premature neonates at Shahid Sadoughi hospital in Yazd. The first group Prematurity received the initial dose of 5 mg/kg aminophylline diluted in 5% dextrose with a maintenance dose of 2 mg/kg every 8 hours, while the second group received 30 mg/kg of caffeine diluted in 5% dextrose with a 24-hour maintenance dose of 10 mg/kg.
    [Show full text]
  • The Xanthines (Theobromine and Aminophyllin)
    effect of this might conceivably escape detection in THE XANTHINES (THEOBROMINE AND individuals engaged in very heavy work. From this AMINOPHYLLINE) IN THE TREAT- point of view our subjects were particularly favorable for this since of as MENT OF CARDIAC PAIN study, most them, shown in the table, were not engaged in any occupation. HARRY M.D. GOLD, GLYCERYL TRINITRATE TEST NATHANIEL T. M.D. KWIT, Early in the course of the study it was believed AND desirable to HAROLD M.D. restrict the selection of patients to those OTTO, who could establish their qualifications for service in NEW YORK such a study as this by their ability to distinguish An endeavor was made in this study to secure evi- between the efficacy of glyceryl trinitrate taken under dence on the question of whether the xanthines relieve the tongue and a soluble placebo tablet taken in the cardiac pain. same manner for relief during attacks of pain. The SELECTION OF PATIENTS discovery of several patients who found the two equally effective those who had suffered an of The were 100 ambulant in attend- among attack subjects patients thrombosis and were to thoracic ance at the cardiac in whom the of coronary subject pain clinic, diagnosis on effort led us to abandon this restriction. arteriosclerotic heart disease with cardiac pain was made, in accordance with the nomenclature and criteria The results obtained in sixty patients in whom the the New York Heart Association.1 glyceryl trinitrate test was made are of some interest. adopted by These received trinitrate were selected from a total case load of patients glyceryl tablets, %0o They approxi- or cr 0.4 which were mately 700 patients, representing an average sample /4so grain (0.6 mg.), they of the cardiac clinic several racial directed to take under the tongue at the onset of an population, comprising attack of In of these of groups, both native and born.
    [Show full text]